Very high-risk prostate cancer: multimodality treatment will be the new frontier

Detalles Bibliográficos
Autores principales: Campobasso, Davide, Prati, Giuseppe, Frattini, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Polish Urological Association 2017
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656377/
https://www.ncbi.nlm.nih.gov/pubmed/29104799
http://dx.doi.org/10.5173/ceju.2017.1535
_version_ 1783273697956593664
author Campobasso, Davide
Prati, Giuseppe
Frattini, Antonio
author_facet Campobasso, Davide
Prati, Giuseppe
Frattini, Antonio
author_sort Campobasso, Davide
collection PubMed
description
format Online
Article
Text
id pubmed-5656377
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Polish Urological Association
record_format MEDLINE/PubMed
spelling pubmed-56563772017-11-03 Very high-risk prostate cancer: multimodality treatment will be the new frontier Campobasso, Davide Prati, Giuseppe Frattini, Antonio Cent European J Urol Letters to the Editor Polish Urological Association 2017-08-16 2017 /pmc/articles/PMC5656377/ /pubmed/29104799 http://dx.doi.org/10.5173/ceju.2017.1535 Text en Copyright by Polish Urological Association http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
spellingShingle Letters to the Editor
Campobasso, Davide
Prati, Giuseppe
Frattini, Antonio
Very high-risk prostate cancer: multimodality treatment will be the new frontier
title Very high-risk prostate cancer: multimodality treatment will be the new frontier
title_full Very high-risk prostate cancer: multimodality treatment will be the new frontier
title_fullStr Very high-risk prostate cancer: multimodality treatment will be the new frontier
title_full_unstemmed Very high-risk prostate cancer: multimodality treatment will be the new frontier
title_short Very high-risk prostate cancer: multimodality treatment will be the new frontier
title_sort very high-risk prostate cancer: multimodality treatment will be the new frontier
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656377/
https://www.ncbi.nlm.nih.gov/pubmed/29104799
http://dx.doi.org/10.5173/ceju.2017.1535
work_keys_str_mv AT campobassodavide veryhighriskprostatecancermultimodalitytreatmentwillbethenewfrontier
AT pratigiuseppe veryhighriskprostatecancermultimodalitytreatmentwillbethenewfrontier
AT frattiniantonio veryhighriskprostatecancermultimodalitytreatmentwillbethenewfrontier

Ejemplares similares